Wael Lasheen1, Declan Walsh. 1. The Harry R Horvitz Center for Palliative Medicine, Department of Solid Tumor Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA.
Abstract
BACKGROUND: Controversy exists as what constitutes the cancer anorexia-cachexia syndrome (CACS), and whether it truly is a distinct clinical disorder. In this study, we aimed to: (1) assess if CACS is a distinct clinical disorder, (2) identify the symptoms characteristic of CACS, (3) evaluate CACS impact on patient outcomes (symptom burden and survival time from referral). METHODS: Consecutive patients referred to palliative medicine were assessed by 38-symptom questionnaire. Demographics, Eastern Cooperative Oncology Group (ECOG), disease and extent, and survival were recorded. CACS, defined as anorexia plus weight loss (>10% of pre-illness weight). For analysis, patients were divided into four groups: (1) group CACS; (2) group A (only anorexia, NO >10% pre-illness weight loss); (3) group WL (weight loss >10% pre-illness weight only but NO anorexia); and (4) group N (NO weight loss >10% pre-illness weight and NO anorexia). Symptoms present in > or =5%, and patients with complete data were analyzed. RESULTS: Four hundred eighty-four patients had complete data, metastatic cancer, and 26 symptoms present in > or =5%. Groups had significantly different ECOG, symptom burden, and survival. Significantly different symptom prevalence between groups: dry mouth,*early satiety,*constipation,*nausea,*taste changes,*vomiting,*dysphagia,*fatigue,*weak,*lack of energy, insomnia, dyspnea, depression, hoarseness, and anxiety. The nine symptoms with asterisk were CACS specific. Symptom Burden: CACS independently predicted greatest burden. Survival: Group N had significantly longer survival. CONCLUSIONS: CACS appeared to be a distinct disorder with unique clinical characteristics in our advanced cancer population. Nine other symptoms constituted CACS. CACS independently predicted higher symptom burden. CACS absence predicted longer survival. More evidence is needed to better characterize this syndrome and generate a valid CACS consensus. A comprehensive validated CACS assessment instrument is required.
BACKGROUND: Controversy exists as what constitutes the cancer anorexia-cachexia syndrome (CACS), and whether it truly is a distinct clinical disorder. In this study, we aimed to: (1) assess if CACS is a distinct clinical disorder, (2) identify the symptoms characteristic of CACS, (3) evaluate CACS impact on patient outcomes (symptom burden and survival time from referral). METHODS: Consecutive patients referred to palliative medicine were assessed by 38-symptom questionnaire. Demographics, Eastern Cooperative Oncology Group (ECOG), disease and extent, and survival were recorded. CACS, defined as anorexia plus weight loss (>10% of pre-illness weight). For analysis, patients were divided into four groups: (1) group CACS; (2) group A (only anorexia, NO >10% pre-illness weight loss); (3) group WL (weight loss >10% pre-illness weight only but NO anorexia); and (4) group N (NO weight loss >10% pre-illness weight and NO anorexia). Symptoms present in > or =5%, and patients with complete data were analyzed. RESULTS: Four hundred eighty-four patients had complete data, metastatic cancer, and 26 symptoms present in > or =5%. Groups had significantly different ECOG, symptom burden, and survival. Significantly different symptom prevalence between groups: dry mouth,*early satiety,*constipation,*nausea,*taste changes,*vomiting,*dysphagia,*fatigue,*weak,*lack of energy, insomnia, dyspnea, depression, hoarseness, and anxiety. The nine symptoms with asterisk were CACS specific. Symptom Burden: CACS independently predicted greatest burden. Survival: Group N had significantly longer survival. CONCLUSIONS: CACS appeared to be a distinct disorder with unique clinical characteristics in our advanced cancer population. Nine other symptoms constituted CACS. CACS independently predicted higher symptom burden. CACS absence predicted longer survival. More evidence is needed to better characterize this syndrome and generate a valid CACS consensus. A comprehensive validated CACS assessment instrument is required.
Authors: Marita Fouladiun; Ulla Körner; Ingvar Bosaeus; Peter Daneryd; Anders Hyltander; Kent G Lundholm Journal: Cancer Date: 2005-05-15 Impact factor: 6.860
Authors: J Feliu; M González-Barón; A Berrocal; A Artal; A Ordóñez; P Garrido; P Zamora; M L García de Paredes; J M Montero Journal: Am J Clin Oncol Date: 1992-10 Impact factor: 2.339
Authors: C L Loprinzi; A M Bernath; D J Schaid; J A Malliard; L M Athmann; J C Michalak; L K Tschetter; A K Hatfield; R F Morton Journal: Oncology Date: 1994-10 Impact factor: 2.935
Authors: N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes Journal: J Natl Cancer Inst Date: 1993-03-03 Impact factor: 13.506
Authors: W D Dewys; C Begg; P T Lavin; P R Band; J M Bennett; J R Bertino; M H Cohen; H O Douglass; P F Engstrom; E Z Ezdinli; J Horton; G J Johnson; C G Moertel; M M Oken; C Perlia; C Rosenbaum; M N Silverstein; R T Skeel; R W Sponzo; D C Tormey Journal: Am J Med Date: 1980-10 Impact factor: 4.965
Authors: David Hui; Carlos Eduardo Paiva; Egidio G Del Fabbro; Christopher Steer; Jane Naberhuis; Marianne van de Wetering; Paz Fernández-Ortega; Tatsuya Morita; Sang-Yeon Suh; Eduardo Bruera; Masanori Mori Journal: Support Care Cancer Date: 2019-03-13 Impact factor: 3.603
Authors: Stephanie H Greco; Lena Tomkötter; Anne-Kristin Vahle; Rae Rokosh; Antonina Avanzi; Syed Kashif Mahmood; Michael Deutsch; Sara Alothman; Dalia Alqunaibit; Atsuo Ochi; Constantinos Zambirinis; Tasnima Mohaimin; Mauricio Rendon; Elliot Levie; Mridul Pansari; Alejandro Torres-Hernandez; Donnele Daley; Rocky Barilla; H Leon Pachter; Daniel Tippens; Hassan Malik; Allal Boutajangout; Thomas Wisniewski; George Miller Journal: PLoS One Date: 2015-07-14 Impact factor: 3.240
Authors: Susanne Blauwhoff-Buskermolen; Jacqueline A E Langius; Annemarie Becker; Henk M W Verheul; Marian A E de van der Schueren Journal: J Cachexia Sarcopenia Muscle Date: 2017-04-26 Impact factor: 12.910
Authors: Maria Maldonado; David L Molfese; Humsini Viswanath; Kaylah Curtis; Ashley Jones; Teresa G Hayes; Marco Marcelli; Sanjay Mediwala; Philip Baldwin; Jose M Garcia; Ramiro Salas Journal: J Cachexia Sarcopenia Muscle Date: 2018-03-25 Impact factor: 12.910